UNSPSC 51401514: Prazepam

This classification denotes a benzodiazepine with the molecular formula C19H17ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q30VCC064M, chemically known as 7-chloro-1-cyclopropylmethyl-5-phenyl-1h-1,4-benzodiazepin-2(3h)-one but generally known as prazepam, which bears US NIH Compound Identifier 4890. European Medicines Agency schedules Prazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10006MIG. The term PRAZEPAM is an International Non-Proprietary Name.

UNSPSC 51401514 Prazepam (Commodity) shows minimal recent state and local procurement activity aligned with its nominal scope. The single recent opportunity tagged under this code — Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 — solicits naloxone and drug deactivation systems for community health initiatives, not prazepam or other benzodiazepines. The mismatch suggests the code may be incorrectly applied to this procurement or reflects data classification inconsistency in the source system rather than active demand for the specific pharmaceutical commodity the code nominally covers.

Seminole County's naloxone procurement represents the only recent state and local opportunity the source identifies under this code. The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a response deadline of July 26, 2023. Without additional recent opportunities in the source block, no meaningful geographic spread or issuing-body mix can be characterized. Business development professionals should treat this code as inactive for prazepam procurement purposes unless downstream research surfaces state or local demand for the specific pharmaceutical that the code's name denotes; the current signal does not support pursuit strategy development.